Announcements Trials

Browse Landscape

Status

Completed 4 Recruiting 3 Terminated 2 Unknown 1 No longer available 1 Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 12 Thoracic 6 Endocrine 3 Head & Neck 2 Breast 2 Sarcoma 1 Other solid neoplasm 1 NET 1

Conditions

Neuroendocrine Tumor Grade 3 1

Interventions

lutetium Lu 177 dotatate 4 lanreotide 3 Temozolomide 3 177Lu-octreotide, DOTA(0)-Tyr(3)- 3 (177)Lu-DOTA-EB-TATE 3 anlotinib 2 Positron Emission Tomography Computed Tomography 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Metformin 2 Fluorodeoxyglucose F18 2 Everolimus 2 Etoposide 2 Cisplatin 2 Capecitabine 2 Biopsy 2 surufatinib 1 sintilimab 1 regorafenib 1 recombinant interferon alpha 2b-like protein 1 pembrolizumab 1 gallium Ga 68 dotatate 1 copper dotatate CU-64 1 cabozantinib 1 amino-acid, glucose, and electrolyte solution 1 Yttrium-90 1 Tomography, Emission-Computed, Single-Photon 1 Thalidomide 1 Tegafur 1 Surgical Procedures, Operative 1 Somatostatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × surufatinib × NET × Clear all

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡